FDA approves PENBRAYA™, the first and only Preventive Vaccine for Meningococcal Disease in Adolescents

Published: October 2023


On 20 October 2023, Pfizer announced the Food and Drug Administration (FDA) approval for PENBRAYA™, a novel preventive vaccine. This vaccine is the first of its kind, offering protection against the primary serogroups responsible for meningococcal disease in individuals aged 10 to 25 years. 

PENBRAYA is an amalgamation of components from two distinct meningococcal vaccines, Trumenba® (targeting meningococcal group B) and Nimenrix® (addressing meningococcal groups A, C, W-135, and Y conjugate), designed to safeguard against the five most prevalent meningococcal serogroups that are responsible for the majority of invasive meningococcal disease (IMD) cases worldwide. 

According to Roots Analysis, the preventive vaccine market is estimated to be worth $94 million in 2030 and is expected to grow at CAGR of 14% during the forecast period.

For detailed insights about this domain, check out our report on Preventive Vaccine Market or email sales@rootsanalysis.com

You may also be interested in the following titles: 

  1. Therapeutic Vaccines Market, 2022-2035
  2. mRNA Therapeutics and Vaccine Market, 2022-2035
  3. Viral Vaccine Cell Culture Media Market, 2022-2035

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry